TriSalus Life Sciences (TLSI) Cash from Investing Activities (2022 - 2026)
TriSalus Life Sciences' (TLSI) quarterly Cash from Investing Activities came in at -$141000.0 in Q1 2026, up 80.25% year-on-year from -$78223.8 in Q1 2025, and down 243.9% quarter-over-quarter from -$41000.0 in Q4 2025.
TriSalus Life Sciences (TLSI) Cash from Investing Activities (2022 - 2026) Analysis & Trends
TriSalus Life Sciences' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$141000.0 for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 80.25% year-over-year to -$141000.0 in Q1 2026; TTM through Mar 2026 was -$265000.0, a 73.31% increase from a year earlier, with the FY2025 full-year figure at -$838000.0, down 142.9% from the prior year.
- Cash from Investing Activities fell to -$141000.0 in Q1 2026 per TLSI's latest filing, from -$41000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $93000.0 in Q2 2025 and bottomed at -$1.6 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is -$74000.0 (2023), against an average of -$276352.9.
- Biggest YoY gain for Cash from Investing Activities was 255.0% in 2025; the steepest drop was 981.82% in 2025.
- Year by year, Cash from Investing Activities stood at -$272000.0 in 2022, then sank by 36.76% to -$372000.0 in 2023, then jumped by 86.56% to -$50000.0 in 2024, then climbed by 18.0% to -$41000.0 in 2025, then plunged by 243.9% to -$141000.0 in 2026.
- Per Business Quant, the three latest TLSI Cash from Investing Activities figures stand at -$141000.0 (Q1 2026), -$41000.0 (Q4 2025), and -$176000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | TriSalus Life Sciences | 222.14 Mn | 165.58 Mn | 7.67 Mn | -141,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -141,000.00 |
| Mar 31, 2026 | -141,000.00 |
| Dec 31, 2025 | -41,000.00 |
| Dec 31, 2025 | -41,000.00 |
| Sep 30, 2025 | -176,000.00 |
| Sep 30, 2025 | -176,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Mar 31, 2025 | -714,000.00 |
| Mar 31, 2025 | -714,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Dec 31, 2024 | -50,000.00 |
| Sep 30, 2024 | -169,000.00 |
| Sep 30, 2024 | -169,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -66,000.00 |
| Mar 31, 2024 | -66,000.00 |
| Dec 31, 2023 | -372,000.00 |
| Dec 31, 2023 | -372,000.00 |